Your browser doesn't support javascript.
loading
Design of a Recombinant Multivalent Epitope Vaccine Based on SARS-CoV-2 and Its Variants in Immunoinformatics Approaches.
Yu, Mingkai; Zhu, Yuejie; Li, Yujiao; Chen, Zhiqiang; Li, Zhiwei; Wang, Jing; Li, Zheng; Zhang, Fengbo; Ding, Jianbing.
Afiliação
  • Yu M; Department of Immunology, School of Basic Medical Sciences, Xinjiang Medical University, Urumqi, China.
  • Zhu Y; Xinjiang Key Molecular Biology Laboratory of Endemic Disease, Xinjiang Medical University, Urumqi, China.
  • Li Y; Reproductive Medicine Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
  • Chen Z; Department of Blood Transfusion, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
  • Li Z; Department of Immunology, School of Basic Medical Sciences, Xinjiang Medical University, Urumqi, China.
  • Wang J; Xinjiang Key Molecular Biology Laboratory of Endemic Disease, Xinjiang Medical University, Urumqi, China.
  • Li Z; Clinical Laboratory Center, Xinjiang Uygur Autonomous Region People's Hospital, Urumqi, China.
  • Zhang F; Xinjiang Laboratory of Respiratory Disease Research, Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University, Urumqi, China.
  • Ding J; Xinjiang Laboratory of Respiratory Disease Research, Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University, Urumqi, China.
Front Immunol ; 13: 884433, 2022.
Article em En | MEDLINE | ID: mdl-35603198
The development of an effective multivalent vaccine against SARS-CoV-2 variants is an important means to improve the global public health situation caused by COVID-19. In this study, we identified the antigen epitopes of the main global epidemic SARS-CoV-2 and mutated virus strains using immunoinformatics approach, and screened out 8 cytotoxic T lymphocyte epitopes (CTLEs), 17 helper T lymphocyte epitopes (HTLEs), 9 linear B-cell epitopes (LBEs) and 4 conformational B-cell epitopes (CBEs). The global population coverage of CTLEs and HTLEs was 93.16% and 99.9% respectively. These epitopes were spliced together by corresponding linkers and recombined into multivalent vaccine. In silico tests, the vaccine protein was a non-allergen and the docking with TLR-3 molecule showed a strong interaction. The results of immune simulation showed that the vaccine may be helpful to initiate both cellular and humoral immunity against all VOC. The optimistic immunogenicity of the vaccine was confirmed in vivo and in vitro finally. Therefore, our vaccine may have potential protection against SARS-CoV-2 and its variants.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China